Carter Gould
Stock Analyst at Cantor Fitzgerald
(3.83)
# 697
Out of 5,111 analysts
215
Total ratings
56.69%
Success rate
7.01%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Maintains: Neutral | $305 → $315 | $326.74 | -3.59% | 18 | Nov 6, 2025 | |
| NUVL Nuvalent | Maintains: Overweight | $100 → $112 | $102.63 | +9.13% | 2 | Oct 31, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $925 → $985 | $1,054.29 | -6.57% | 14 | Oct 31, 2025 | |
| GILD Gilead Sciences | Reiterates: Overweight | $135 | $118.78 | +13.66% | 16 | Oct 31, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $678 → $740 | $746.36 | -0.85% | 21 | Oct 29, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $245 → $250 | $223.67 | +11.77% | 18 | Oct 9, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $485 | $454.96 | +6.60% | 4 | Aug 5, 2025 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Neutral | $55 | $54.23 | +1.42% | 16 | Apr 23, 2025 | |
| PFE Pfizer | Initiates: Neutral | $24 | $25.53 | -5.99% | 15 | Apr 22, 2025 | |
| PCVX Vaxcyte | Initiates: Overweight | n/a | $43.67 | - | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $85 | $98.27 | -13.50% | 11 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $160 → $165 | $148.74 | +10.93% | 12 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $35.85 | -44.21% | 6 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $190 → $180 | $171.50 | +4.96% | 24 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $60 | $15.82 | +279.27% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3 | $0.74 | +306.23% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $1.34 | +571.64% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $95 | $62.02 | +53.18% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $20 | $6.61 | +202.57% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $73 | $66.33 | +10.06% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $1.39 | +763.31% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $1.5 | $3.56 | -57.87% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $2.25 | $0.12 | +1,764.13% | 4 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $392 → $380 | $162.77 | +133.46% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 → $82 | $97.03 | -15.49% | 5 | Jan 16, 2019 |
Amgen
Nov 6, 2025
Maintains: Neutral
Price Target: $305 → $315
Current: $326.74
Upside: -3.59%
Nuvalent
Oct 31, 2025
Maintains: Overweight
Price Target: $100 → $112
Current: $102.63
Upside: +9.13%
Eli Lilly and Company
Oct 31, 2025
Maintains: Overweight
Price Target: $925 → $985
Current: $1,054.29
Upside: -6.57%
Gilead Sciences
Oct 31, 2025
Reiterates: Overweight
Price Target: $135
Current: $118.78
Upside: +13.66%
Regeneron Pharmaceuticals
Oct 29, 2025
Maintains: Overweight
Price Target: $678 → $740
Current: $746.36
Upside: -0.85%
AbbVie
Oct 9, 2025
Maintains: Overweight
Price Target: $245 → $250
Current: $223.67
Upside: +11.77%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Overweight
Price Target: $535 → $485
Current: $454.96
Upside: +6.60%
Bristol-Myers Squibb Company
Apr 23, 2025
Reiterates: Neutral
Price Target: $55
Current: $54.23
Upside: +1.42%
Pfizer
Apr 22, 2025
Initiates: Neutral
Price Target: $24
Current: $25.53
Upside: -5.99%
Vaxcyte
Apr 22, 2025
Initiates: Overweight
Price Target: n/a
Current: $43.67
Upside: -
Apr 22, 2025
Initiates: Neutral
Price Target: $85
Current: $98.27
Upside: -13.50%
Dec 23, 2024
Maintains: Overweight
Price Target: $160 → $165
Current: $148.74
Upside: +10.93%
Nov 1, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $35.85
Upside: -44.21%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $190 → $180
Current: $171.50
Upside: +4.96%
Aug 14, 2024
Maintains: Overweight
Price Target: $200 → $60
Current: $15.82
Upside: +279.27%
Jun 13, 2024
Maintains: Overweight
Price Target: $7 → $3
Current: $0.74
Upside: +306.23%
Jun 11, 2024
Initiates: Overweight
Price Target: $9
Current: $1.34
Upside: +571.64%
May 23, 2024
Maintains: Overweight
Price Target: $100 → $95
Current: $62.02
Upside: +53.18%
Apr 16, 2024
Maintains: Overweight
Price Target: $25 → $20
Current: $6.61
Upside: +202.57%
Feb 29, 2024
Maintains: Overweight
Price Target: $62 → $73
Current: $66.33
Upside: +10.06%
May 5, 2023
Maintains: Overweight
Price Target: $14 → $12
Current: $1.39
Upside: +763.31%
Mar 21, 2023
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $3.56
Upside: -57.87%
Aug 16, 2022
Maintains: Equal-Weight
Price Target: $2.5 → $2.25
Current: $0.12
Upside: +1,764.13%
Jan 20, 2022
Maintains: Equal-Weight
Price Target: $392 → $380
Current: $162.77
Upside: +133.46%
Jan 16, 2019
Downgrades: Neutral
Price Target: $75 → $82
Current: $97.03
Upside: -15.49%